Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[ANCA-associated vasculitis].

R A Sinico1, E Sabadini, R Boeri

  • 1Unita' Operativa di Nefrologia e Centro di Immunologia Clinica e Reumatologia, Milano, Italy. renato.sinico@oscb.sined.net

Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia
|August 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic approach to hypersensitivity reactions to iodinated contrast media: a single-center experience on 98 patients.

European annals of allergy and clinical immunology·2020
Same author

Allergic reactions after vaccination: translating guidelines into clinical practice.

European annals of allergy and clinical immunology·2019
Same author

Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.

Journal of nephrology·2017
Same author

The inter-observer reading variability in anti-nuclear antibodies indirect (ANA) immunofluorescence test: A multicenter evaluation and a review of the literature.

Autoimmunity reviews·2017
Same author

Immunology of membranous nephropathy: from animal models to humans.

Clinical and experimental immunology·2015
Same author

Can HLA-DRB4 Help to Identify Asthmatic Patients at Risk of Churg-Strauss Syndrome?

ISRN rheumatology·2014
Same journal

[Rufus of Ephesus, On gout].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

A Case Report and Literature Review: Chlorhexidine-induced anaphylaxis in a hemodialysis patient.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

New Frontiers in the Treatment of Chronic Kidney Disease-associated Pruritus: A Case of Hemoperfusion with HA130.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

Fibronectin Glomerulopathy: A Case Report of Membranoproliferative Glomerulonephritis.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

Sodium Disorders in Multiple Myeloma: Beyond Pseudohyponatremia to Clinical Pitfalls and Mechanistic Insights.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

Acute Kidney Injury and Early Diagnostic Biomarkers: A Narrative Literature Review.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
See all related articles

Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AASV) requires prompt treatment with cyclophosphamide and prednisone to induce remission. Maintenance therapy with azathioprine is recommended after remission is achieved.

Area of Science:

  • Nephrology
  • Rheumatology
  • Immunology

Context:

  • Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AASV) encompasses several primary vasculitis syndromes.
  • These syndromes, including Wegener's granulomatosis and microscopic polyangiitis, share key clinical and histological features.
  • Untreated AASV leads to progressive organ failure and fatal outcomes.

Purpose:

  • To outline the established treatment protocols for AASV.
  • To discuss the induction and maintenance phases of AASV therapy.
  • To provide guidance on managing AASV with renal involvement.

Summary:

  • The standard treatment for AASV involves a combination of cyclophosphamide and prednisone for remission induction.
  • For patients with renal involvement (serum creatinine <500 mL/L), oral prednisone with gradual tapering and cyclophosphamide are recommended.

Related Experiment Videos

  • Azathioprine should replace cyclophosphamide once remission is achieved (typically 3-6 months), with treatment continuing for at least one year post-remission.
  • In cases of severe renal impairment (serum creatinine >500 mL/L) or oliguria, methylprednisolone pulses and/or plasma exchange should be considered.

    • Impact:

    • Establishes a clear treatment pathway for AASV, improving patient outcomes.
    • Highlights the importance of differentiating treatment strategies based on renal involvement severity.
    • Contributes to the understanding of long-term management and remission maintenance in AASV.